Interleukin Genetics Launches iPhone® and iPad® App for Its Inherent Health® Services

Inherent Diet and Nutrient AnalyzerTM Allows Easy Tracking and Analysis of Food Consumption, Nutrients and Exercise for Individuals

WALTHAM, Mass.--(BUSINESS WIRE)-- Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the launch of a free app for the iPhone and iPad that links the Company’s comprehensive suite of DNA-based weight loss web tools on the Inherent Health website ( to users’ mobile devices. The new Inherent Diet and Nutrient AnalyzerTM app is available via the iTunes® App Store and allows users to input foods and exercises directly into their Inherent Health Diet and Nutrient Analyzer (iDNA) accounts. These DNA-based weight loss web tools provide customers with a convenient and informative way to manage their diet and exercise plans based on their specific genetic makeup as indicated by the results of their Inherent Health Weight Management Genetic Test.

“The availability of the free app for these popular mobile devices should allow greater convenience to our customers to track their calories and macronutrient levels,” said Lewis H. Bender, CEO, Interleukin Genetics. “We’re excited to offer a valuable new tool to our Inherent Health Weight Management Services that helps our customers navigate their weight loss journey more effectively.”

About the Inherent Diet and Nutrient AnalyzerTM App

The free Inherent Diet and Nutrient AnalyzerTM app includes a calorie and macronutrient tracking tool. Customers record calories consumed for more than 100,000 different foods and energy burned for approximately 10,000 exercises. The Analyzer library, now available on the iPhone and iPad, can determine a food’s macronutrient content in terms of fat, carbohydrates and protein. In addition, the application matches a person’s genetics to specific menus, provides recipes for low-fat, low-carb or balanced meals.

Customers on the Inherent Health web site can find the new Inherent Diet and Nutrient Analyzer® app under the Health & Fitness category of the AppStore® and begin downloading suggested meal plans, create grocery lists as well as interact with an online community of persons with similar genetic diet IDs via chat rooms and blogs. While some of the features are only available through a premium service package billed monthly, for the first 30 days after activating their iDNA account, customers can enjoy the full suite of all weight loss web products for free.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® and PST® brands. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information please visit

Certain statements contained herein are “forward-looking” statements, including statements that availability of new app will be a valuable tool that offers greater convenience and helps our customers achieve their goals more effectively. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2011 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


Interleukin Genetics, Inc.
Jennifer Violette, 781-398-0700 ext.1210
Public Relations
[email protected]
Interleukin Genetics, Inc.
Eliot Lurier, 781-398-0700 ext.1204
Chief Financial Officer
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Consumer Electronics  Internet  Software  Health  Fitness & Nutrition  Genetics  Mobile/Wireless  Other Health



Suggested Articles

The COVID-19 pandemic is driving enormous demand for virtual mental health care services. Here is how much utilization has increased during COVID-19.

Ambulatory EHR provider NextGen Healthcare saw its quarterly revenue grew 4% to $140 million and earnings topped Wall Street projections.

Blue Cross NC is launching two new digital programs targeting smoking cessation and Type 2 diabetes management next month at no cost to members.